LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
Frequently asked questions
What sector does LakeShore Biopharma Co., Ltd (LSBCF) operate in?
LakeShore Biopharma Co., Ltd belongs to the Other sector and operates in the Biotechnology industry.
What is LakeShore Biopharma Co., Ltd (LSBCF) current stock price?
As of the latest data, LakeShore Biopharma Co., Ltd stock price is $0.07, with a previous close of $0.07.
What is LakeShore Biopharma Co., Ltd (LSBCF) current market capitalization?
LakeShore Biopharma Co., Ltd market cap is approximately 2.76 million.
What is LakeShore Biopharma Co., Ltd (LSBCF) Earnings Per Share (EPS)?
The trailing EPS is -$0.77.
Does LakeShore Biopharma Co., Ltd (LSBCF) pay dividends?
No. LakeShore Biopharma Co., Ltd does not pay a dividend.
What is LakeShore Biopharma Co., Ltd (LSBCF) beta (volatility) score?
LakeShore Biopharma Co., Ltd has a beta of 1.007, meaning its volatility is roughly in line with the market.
